
Merck closes SciBrunch KRAS licence worth up to US$2.13B
The closed SPR2015 deal carries a US$400M upfront payment; further value depends on development and commercial milestones.

The cannabis banking platform expects SHFS to keep its Nasdaq ticker and round fractional holdings up when split-adjusted trading begins Sept. 30.

The closed SPR2015 deal carries a US$400M upfront payment; further value depends on development and commercial milestones.

The three-year ceiling includes options; DLH did not disclose the funded base period or update its US$408.5M June 30 backlog.
The Sept. 25 adult Parkinson's approval clears one condition for a payment-rights purchase expected to close Sept. 29.
The 18-month HHS award covers all three Xacta modules plus integration, training and migration services.

Hanwa and JOGMEC would take 15% at closing, while NextSource targets a second-half 2027 ramp-up for the plant's first phase.

The perpetual, royalty-free agreement covers two brands, while a Texas launch still requires final state licensure and regulatory approval.

The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.

Its Texas subsidiary would pay PsyLabs the milestones for the first drug candidate; the binding terms lapse without a definitive agreement by Nov. 30.
Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.
Most of the award remains unfunded as Amprius targets 12 million cells a year from a converted U.S. line by early 2028.
The AIM software group ended a process begun in March and reported £6.3 million revenue for the six months to July 31.
The Los Nanos assays include mineralization beyond the existing model, but the sector has no reserves and remains outside the mine plan.
The Western Australian deposit now contains 526,000 indicated ounces, with the larger estimate set for a Sandstone study due in the December quarter.
The Sept. 26 first pour came before the original second-quarter 2027 schedule; the oxide circuit is targeted for commercial production in late 2026.
The first Cape Station block is due for contractual commercial operation by Oct. 1, while two more blocks target Jan. 1, 2027.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Smackover Lithium can send optional tonnes to another buyer while it seeks about US$1.1 billion of debt and an investment decision in 2026.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The 40-patient tipelukast study missed its week-24 liver-fat and triglyceride comparisons, although secondary HDL measures improved.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The Sept. 28 vote approved articles changes, preferred allotments and market repurchases; a possible IPO still needs an FCA-approved prospectus.
The four-year line starts at SOFR plus 175 basis points and can back utility and equipment obligations with letters of credit.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The term starts when Building One is ready for service; Fermi gave no date or contract value in its Sept. 24 announcement.

OPG's Sept. 25 supplier post names ATS's tooling and a 125,000-square-foot facility addition without stating a contract value or delivery date.

SIDEX and NQ Mining Investment lead the flow-through sale, priced at C$0.145 a share and expected to close about Sept. 29.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.

Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.